Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Ghosal, Samit ^a   Sinha, Binayak ^b  

^a Nightingale Hospital   (India)

^b AMRI HOSPITALS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CARDIOVASCULAR DISEASES; COMPLICATION; NON INSULIN DEPENDENT DIABETES MELLITUS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84948798569     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/1643496     Document Type: Review

References (29)

1. B. Leibel, "An analysis of the University Group Diabetes Study Program: data results and conslusions," Canadian Medical Association Journal, vol. 105, no. 3, pp. 292-294, 1971.
2. P. Home, "Safety of PPAR agonists," Diabetes Care, vol. 34, supplement 2, pp. S215-S219, 2011.
3. Product Monograph, ACTOS, 2012, http://www.takedacanada.com/actospm/~/media/countries/ca/files/product%20pdfs/actos%20pm%20eng%2018-may-2012.pdf.
4. J. A. Dormandy, B. Charbonnel, D. J. A. Eckland et al., "Secondary prevention ofmacrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial in macro Vascular Events): a randomised controlled trial," The Lancet, vol. 366, no. 9493, pp. 1279-1289, 2005.
5. M. Fisher, "Improving cardiovascular risk - Applying evidencebased medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes," International Journal of Clinical Practice, vol. 63, no. 9, pp. 1354-1368, 2009.
6. S. E. Nissen and K. Wolski, "Effect of rosiglitazone on the risk ofmyocardial infarction and death fromcardiovascular causes," The New England Journal of Medicine, vol. 356, no. 24, pp. 2457-2471, 2007.
7. U.S. Department of Health and Human Services and Food and Drug Administration Center for Drug Evaluation and Research (CDER), Guidance for Industry Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, 2008, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf.
8. A. J. Scheen, "A review of gliptins in 2011," Expert Opinion on Pharmacotherapy, vol. 13, no. 1, pp. 81-99, 2012.
9. R. Arechavaleta, T. Seck, Y. Chen et al., "Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial," Diabetes, Obesity and Metabolism, vol. 13, no. 2, pp. 160-168, 2011.
10. A. J. Scheen, "Cardiovascular effects of gliptins," Nature Reviews Cardiology, vol. 10, no. 2, pp. 73-84, 2013.
11. A. J. Tremblay, B. Lamarche, I. Kelly et al., "Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes," Diabetes, Obesity and Metabolism, vol. 16, no. 12, pp. 1223-1229, 2014.
12. R. P. Mason, R. F. Jacob, R. Kubant, A. Ciszewski, J. J. Corbalan, and T. Malinski, "Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats," Journal of Cardiovascular Pharmacology, vol. 60, no. 5, pp. 467-473, 2012.
13. FDA Briefing Materials-Saxagliptin, 2009, http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b1-01-FDA.pdf.
14. O. E. Johansen, D. Neubacher, M. von Eynatten, S. Patel, and H.-J. Woerle, "Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme," Cardiovascular Diabetology, vol. 11, article 3, 2012.
15. B. M. Scirica, D. L. Bhatt, E. Braunwald et al., "The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study," American Heart Journal, vol. 162, no. 5, pp. 818.e6-825.e6, 2011.
16. B. M. Scirica, D. L. Bhatt, E. Braunwald et al., "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus," The New England Journal of Medicine, vol. 369, no. 14, pp. 1317-1326, 2013.
17. J. B. Green, M. A. Bethel, P. W. Armstrong et al., "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes," The New England Journal of Medicine, vol. 373, no. 3, pp. 232-242, 2015.
18. V. P. Sanon, S. Sanon, S.V. Pham, and R. Chilton, "Play of chance versus concerns regarding dipeptidyl peptidase-4 inhibitors: heart failure and diabetes," Clinical Diabetes, vol. 32, no. 3, pp. 121-126, 2014.
19. W. B. White, G. L. Bakris, R.M. Bergenstal et al., "EXamination of CArdiovascular Outco Mes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome," American Heart Journal, vol. 162, no. 4, pp. 620.e1-626.e1, 2011.
20. W. B. White, C. P. Cannon, S. R. Heller et al., "Alogliptin after acute coronary syndrome in patients with type 2 diabetes," The New England Journal of Medicine, vol. 369, no. 14, pp. 1327-1335, 2013.
21. E. Standl and O. Schnell, "DPP-4 inhibitors and risk of heart failure EXAMINEd," The Lancet, vol. 385, no. 9982, pp. 2022-2024, 2022.
22. Briefing Material, NDA 22350: Saxagliptin (Onglyza). NDA 200678: Saxagliptin/Metformin (Kombiglyze XR). April 2015, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/UCM442060.pdf.
23. EMDAC Briefing Document Cardiovascular Outcomes Trial EXAMINE/NDAs 022271, 022426, & 203414 Nesina (alogliptin), Oseni (alogliptin/pioglitazone), & Kazano (alogliptin/metforminHCl), 2015, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM442062.pdf.
24. J. B. Green, M. A. Bethel, S. K. Paul et al., "Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease," American Heart Journal, vol. 166, no. 6, pp. 983.e7-989.e7, 2013.
25. UK Prospective Diabetes Study (UKPDS) Group, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)," The Lancet, vol. 352, no. 9131, pp. 854-865, 1998.
26. Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA), 2015, https://clinicaltrials.gov/ct2/show/NCT01897532.
27. N. Marx, J. Rosenstock, S. E. Kahn et al., "Design and baseline characteristics of the Cardiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA)," Diabetes & Vascular Disease Research, vol. 12, no. 3, pp. 164-174, 2015.
28. R. R. Holman, S. K. Paul, M.A. Bethel, D. R. Matthews, and H. A. W. Neil, "10-Year follow-up of intensive glucose control in type 2 diabetes," The New England Journal of Medicine, vol. 359, no. 15, pp. 1577-1589, 2008.
29. H. C. Gerstein, J. Bosch, G. R. Dagenais et al., "Basal insulin and cardiovascular and other outcomes in dysglycemia," The New England Journal of Medicine, vol. 367, no. 4, pp. 319-328, 2012.